Erratum: Body Composition Changes after Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s (Clin Infect Dis (2016) 62:7 (853-862) DOI: 10.1093/cid/ciw017);Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s

Clinical Infectious Diseases

Volumn 62, Issue 7, 2016, Pages 853-862

  McComsey, Grace A ^a   Moser, Carlee ^b   Currier, Judith ^c   Ribaudo, Heather J ^b   Paczuski, Pawel ^b   Dubé, Michael P ^d   Kelesidis, Theodoros ^c   Rothenberg, Jennifer ^e   Stein, James H ^f   Brown, Todd T ^g  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

body composition; limb fat; lipoatrophy; lipodystrophy; visceral fat

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BIOLOGICAL MARKER; CD14 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; D DIMER; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABDOMINAL FAT; ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT MASS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS FAT; T LYMPHOCYTE; WEIGHT CHANGE; BLOOD; CONTROLLED STUDY; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VIROLOGY; VIRUS LOAD; WEIGHT GAIN;

ABDOMINAL FAT; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RALTEGRAVIR POTASSIUM; RNA, VIRAL; VIRAL LOAD; WEIGHT GAIN;

EID: 84959477701     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa1740     Document Type: Erratum

References (29)

1. Duran S, SavesM, Spire B, et al. Failure to maintain long-Term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001; 15: 2441-4.
2. Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAARTtreated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther. 2007; 4: 19.
3. Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the Womens Interagency HIV Study. AIDS Behav. 2009; 13: 53-9.
4. McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion. 2004; 4: 111-8.
5. McComsey GA, Libutti DE, ORiordan M, et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther. 2008; 13: 715-22.
6. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009; 23: 1109-18.
7. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011; 53: 185-96.
8. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001; 357: 592-8.
9. Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012; 26: 475-81.
10. Lake JE, McComsey GA, Hulgan TM, et al A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012; 26: 532-40.
11. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-Term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011; 53: 807-16.
12. Stein JH, Ribaudo H, Hodis H, et al A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015; 29: 1775-83.
13. Kelesidis T, Tran TT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015; 61: 651-60.
14. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998; 351: 871-5.
15. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005; 19: 1807-18.
16. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother. 2011; 17: 183-8.
17. Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA. Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res. 2011; 9: 174-9.
18. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010; 55: 39-48.
19. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012; 28: 1184-95.
20. Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. Clin Infect Dis. 2015; 60: 811-20.
21. Podzamczer D, Ferrer E, Martinez E, et al. How much fat loss is needed for lipoatrophy to become clinically evident?. AIDS Res Hum Retroviruses. 2009; 25: 563-7.
22. McComsey GA, Daar ES, ORiordan M, et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DFemtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013; 207: 604-11.
23. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, et al. Association between HLA-B 4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin Infect Dis. 2010; 50: 597-604.
24. Zanone Poma B, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS. 2008; 22: 1769-78.
25. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009; 51: 111-6.
26. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005; 40: 1837-45.
27. Damouche A, Lazure T, Avettand-Fenoel V, et al. Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection. PLoS Pathog. 2015; 11: e1005153.
28. Kredel LI, Siegmund B. Adipose-Tissue and intestinal inflammation-visceral obesity and creeping fat. Front Immunol. 2014; 5: 462.
29. Drouet M, Dubuquoy L, Desreumaux P, Bertin B. Visceral fat and gut inflammation. Nutrition. 2012; 28: 113-7.